Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant

Anti–SARS-CoV-2 antibodies have been detected in up to approximately 70% of solid organ transplant recipients who were given 3 doses of the SARS-CoV-2 vaccine.^1,2 In France, it has been allowed to offer a fourth dose on a case-by-case basis.³ We assessed whether a fourth dose of the SARS-CoV-2 vaccine is associated with improved anti–SARS-CoV-2 antibody concentrations in solid organ transplant recipients in France.

This case series study was conducted from July 1, 2021, to August 5, 2021. A fourth dose of the messenger RNA-based BNT162b2 vaccine (Pfizer-BioNTech) was given to the 37 solid organ transplant recipients, including 5 (13.5%) who had a weak response to the previous 3 doses (antibody concentration <14 binding antibody units [BAU]/mL)⁴ and 31 (83.8%) who had no response to the 3 previous doses. All participants provided oral informed consent and received approval of the medical staff (Table). According to French law (Loi Jardé), anonymous retrospective studies do not require institutional review board approval. This study followed the reporting guideline for case series.

The first 2 doses were given 1 month apart, the third dose was administered a mean (SD) of 57 (17) days after the second dose, and the last dose was given a mean (SD) of 65 (9) days after the third dose. Anti–SARS-CoV-2 spike protein total antibody concentrations were assessed using the Wantaï enzyme-linked immunosorbent assay test. Neutralizing antibody (NAb) titers were assessed using a live virus neutralization assay. Enzyme-linked immunospot assay measuring interferon (IFN)–γ produced by specific SARS-CoV-2 T cells was performed for 14 patients (eMethods in the Supplement). Proportions were compared using the Fisher exact test. Quantitative variables were compared by the Student t test or the Mann-Whitney test. A 2-sided P value <.05 was considered to be statistically significant. All statistical analyses were performed with Prism Software v8.1 (GraphPad).

Of 37 patients included in this case series study, 20 (54.0%) were male, with a mean (SEM) age of 60 (14) years. Anti–SARS-CoV-2 antibodies were detected in 5 of 37 patients (13.5%) before dose 4 and in 18 of 37 patients (48.6%) 1 month later (P = .002). Among the 5 patients who were seropositive before dose 4, the median antibody concentration increased from 4 BAU/mL (range, 1-9 BAU/mL) to 402 BAU/mL (range, 87-508 BAU/mL) at 4 weeks after dose 4 (P < .001) (Figure, A). Neutralizing antibody titers increased from a median of 8 IU/mL (range, 2-32 IU/mL) to 16 IU/mL (range, 4-32 IU/mL) (P = .07).

Among the 31 patients who were seronegative before dose 4, 13 (41.9%) became seropositive (median antibody concentration, 9.5 BAU/mL [range, 1.7-658 BAU/mL]) at 4 weeks after dose 4; 6 patients (19.4%) had antibody concentrations greater than 14 BAU/mL, and 2 (6.5%) had antibody concentrations greater than 140 BAU/mL (Figure, A). Among these patients, the median NAb titer was 8 IU/mL (range, 2-32 IU/mL).

At 4 weeks after dose 4, antibody concentrations were significantly higher among patients who had detectable antibodies before dose 4 than among those who had no response. However, Nab titers at 4 weeks after dose 4 did not differ between responders and nonresponders to 3 doses.

Overall, at 4 weeks after dose 4, 32 of 37 patients (86.5%) had antibody concentrations less than 140 BAU/mL (a threshold providing 12.4% protection among health care workers⁴) and all 37 patients (100%) had NAb titers less than 64 IU/mL. No breakthrough infection was observed during follow-up.

At 4 weeks after D4, the number of SARS-CoV-2–reactive IFN-γ–producing cells was 61.25 spot-forming units (SFUs) per 10⁶ peripheral blood mononuclear cells (PBMCs) (range, 2.5-372.5 SFUs per 10⁶ PBMCs), with 167.5 SFUs per 10⁶ PBMCs (range, 47.5-372.5 SFUs per 10⁶ PBMCs) among seropositive patients and 55 SFU per 10⁶ PBMC (range, 2.5-110 SFUs per 10⁶ PBMC) among seronegative patients (Figure, B).

No serious adverse event or acute rejection was observed after dose 4. One kidney transplant recipient presented with a recurrence of IgA nephropathy. Four patients presented with fatigue and myalgia. One patient indicated gastrointestinal symptoms.

In this case series study, our findings were similar to those of the study by Alejo et al,⁵ in which a fourth dose of SARS-CoV-2 vaccine was associated with slightly improved humoral response among patients with a weak response after 3 doses and with no improvement among those with no response after 3 doses. Neutralizing antibody titers and cellular response were low in both groups. In a study⁶ of 22 healthy volunteers (median age, 59 years), among all individuals, antibody concentrations at 1 month after 2 doses of BNT162b2 vaccine were greater than 140 BAU/mL (median, 1309 BAU/mL [range, 457-7605 BAU/mL]) and NAb titers were greater than 64 IU/mL (median 128 [range, 64-512 IU/mL]). In another study of 20 healthy volunteers (median age, 55 years), the number of SARS-CoV-2–reactive IFN-γ–producing cells at 1 month after 2 doses of BNT162b2 vaccine was 542 SFUs per 10⁶ PBMCs (range, 0-1669 SFUs per 10⁶ PBMCs) (Jacques Izopet, Pharm D, PhD, unpublished data). A limitation of our study was the small number of patients. Other strategies should be tested for solid organ transplant recipients.

Accepted for Publication: September 28, 2021.

Published: November 24, 2021. doi:10.1001/jamanetworkopen.2021.36030

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Kamar N et al. JAMA Network Open.

Corresponding Author: Nassim Kamar, MD, PhD, Department of Nephrology and Organ Transplantation, Toulouse University Hospital, TSA 50032, 31059 Toulouse Cedex 9, France (kamar.n@chu-toulouse.fr).

Author Contributions: Dr Kamar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Kamar, Marion, Del Bello.

Acquisition, analysis, or interpretation of data: Kamar, Abravanel, Marion, Romieu-Mourez, Couat, Izopet.

Drafting of the manuscript: Kamar.

Critical revision of the manuscript for important intellectual content: Kamar, Abravanel, Marion, Couat, Del Bello, Izopet.

Statistical analysis: Kamar, Couat.

Administrative, technical, or material support: Abravanel, Romieu-Mourez, Couat.

Supervision: Abravanel, Del Bello, Izopet.

Conflict of Interest Disclosures: Dr Kamar reported receiving speaker fees and participating in advisory boards for AbbVie, Astellas, Biotest, CSL Behring, Chiesi, Merck Sharp and Dohme, Neovii, Novartis Pharma, Sanofi, Sandoz, Shire, and Takeda and receiving personal fees from AbbVie, Astellas, Biotest, CSL Behring, Chiesi, Merck Sharp and Dohme, Neovii, Novartis Pharma, Sanofi, Sandoz, Shire, and Takeda outside the submitted work. No other disclosures were reported.